Shareholders

Yissum

Established in 1964, Yissum is the technology transfer company responsible for protecting and commercializing the intellectual property developed at the Hebrew University of Jerusalem. With a track record of more than 110 spin-off companies generating over $2 billion in annual sales, Yissum ranks among the top technology companies in the world with over 8,900 patents, 2,500 inventions and 825 licensed technologies.

TEMASEK

Incorporated in 1974, Temasek is an investment company headquartered in Singapore. Supported by 10 offices internationally, Temasek owns a S$275 billion (US$197 billion) portfolio as of 31 March 2017, mainly in Singapore and the rest of Asia.  Temasek’s portfolio covers a broad spectrum of industries: financial services; telecommunications, media & technology; transportation & industrials; consumer & real estate; life sciences & agribusiness; as well as energy & resources.

Invatech Holdings

Invatech Holdings represents private groups of investors from North & South America and Israel.
The company specializes in healthcare-related investments in Israel.

Israeli Institutional funds

  • The Israeli Teachers’ & Kindergarten Study funds – AUM of over $4.5 Billion.
  • The Hebrew University Provident Fund – AUM of over $250 Million.
  • Halman-Aldubi Investment Group manages investments of provident study and pension funds
    with total AUM of over $4 Billion.

Guangxi Wuzhou Pharmaceutical Group

Guangxi Wuzhou Pharmaceutical Group Co., Ltd. is a wholly owned subsidiary of the Guangxi Wuzhou Zongheng Group, a Chinese investment holdings company traded on the Shanghai Stock Exchange (SHA:600252) with a current market cap of approximately US $2.8 Billion. The parent company focuses on health and food products, while Guangxi Wuzhou Pharmaceutical Group is the largest pharmaceutical company in Guangxi, and among the 20 largest pharmaceutical companies in China.

Consensus Business Group (CBG)

Consensus Business Group (“CBG”) is a leading UK-based investment group whose overall portfolio under administration includes investments in over 1,000 technologies in the areas of pharma, biotech, medical technologies, cleantech, agri-tech, food tech, aqua tech, real estate and others. CBG has a particular focus on investments in several leading funds, incubators, innovation laboratories, companies and other direct investments in UK, EU, US and Israel, where it continues to develop its strong ecosystem and partnerships with leading academic institutions, hospital groups, universities, governmental institutions and corporates. CBG has a net asset value in excess of $1,2 bn.